News - OBI Pharma 台灣浩鼎

2019.Dec.19

未分類

Corporate

OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999.

2019.Sep.03

未分類

Corporate

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999

2019.Mar.28

未分類

Corporate

OBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999

2019.Feb.12

未分類

Corporate

New Scientific Research provides link between Globo-series glycosphingolipids (GSLs) antigens and tumor survival in Breast Cancer

2019.Jan.09

未分類

Corporate

OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

2018.Nov.21

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer

2018.Sep.19

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

2018.Jul.08

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)

2018.Apr.19

未分類

Corporate

OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors

2018.Jan.17

未分類

Corporate

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

Announcements

Latest announcements

Events

Latest events